FBXW7 and colorectal carcinoma: Elevated MCL1 is a hallmark of FBW7‐deficient CRC and drives resistance to regorafenib [20, 27], sorafenib [27], microtubule‐targeting agents [25], and Hsp90 inhibitors [26].